News | Radiopharmaceuticals and Tracers | October 12, 2018

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018

Federal legislation would institute separate payment policy for diagnostic radiopharmaceuticals under the Medicare Hospital Outpatient Prospective Payment System (OPPS)

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018

October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical and nuclear pharmacy industries in North America — strongly supports legislation recently introduced by Congressman George Holding (R-NC-2) and Seth Moulton (D-MA-6). This legislation, designated H.R. 6948 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018, would direct the Secretary of Health and Human Services to recognize diagnostic radiopharmaceuticals (RPs) as drugs and institute a separate payment policy under the Medicare Hospital Outpatient Prospective Payment System (OPPS).

According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), more than 20 million Americans benefit each year from nuclear medicine procedures.1 Diagnostic RPs are drugs necessary for all nuclear medicine imaging studies to diagnose and determine the severity of disease. Nuclear medicine imaging procedures are effectively used in the diagnosis and treatment of disease states such as cardiovascular disease, some forms of cancer, Parkinson’s Disease, thyroid disease and epilepsy.

Diagnostic and therapeutic RPs are statutorily considered drugs and are regulated as drugs by the Food and Drug Administration. However, since 2009 diagnostic RPs under the OPPS have been packaged with the procedure into Ambulatory Payment Classifications (APCs) for a bundled payment to hospitals while therapeutic RPs continue to be paid separately. Diagnostic RP costs may vary widely within a nuclear medicine APC with some diagnostic RP costs significantly exceeding the APC payment rate.

The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 will ensure that diagnostic RPs are recognized as drugs and that all diagnostic RPs are appropriately paid under the OPPS. This will safeguard patient access to newer precision diagnostic RPs and support more innovation to improve clinical outcomes and deliver more cost-effective care, according to CORAR.

For more information: www.corar.org

Reference

  1. Society of Nuclear Medicine and Molecular Imaging, http://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=4825

Related Content

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

News | Nuclear Imaging | December 22, 2020
December 22, 2020 — Researchers in the DO...
SHINE executives and project leaders were joined by a City of Janesville official for the groundbreaking ceremony for the new corporate headquarters and therapeutics production facility on the SHINE campus in Janesville, Wis. (Photo: Business Wire)

SHINE executives and project leaders were joined by a City of Janesville official for the groundbreaking ceremony for the new corporate headquarters and therapeutics production facility on the SHINE campus in Janesville, Wis. (Photo: Business Wire)

News | Nuclear Imaging | December 18, 2020
December 18, 2020 — SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000

JNM celebrates 60 years of nuclear medicine research. Image courtesy of Society of Nuclear Medicine and Molecular Imaging.

News | Nuclear Imaging | December 14, 2020
December 14, 2020 — The Journal of Nuclear Medicine
Videos | PET-CT | December 04, 2020
This is an example of Canon's...
Shine Test System paired with the world’s strongest commercial fusion neutron generator manufactured by Phoenix. It can break apart low-enriched uranium to produce moly-99 for medical isotope production.

Shine Test System paired with the world’s strongest commercial fusion neutron generator manufactured by Phoenix. It can break apart low-enriched uranium to produce moly-99 for medical isotope production.

Feature | Nuclear Imaging | November 12, 2020 | By Willow Ascenzo
Medical imaging procedures such as single-photon emission computed tomography (...
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Be sure to register for the American Society for Radiation Oncology's (ASTRO) 62nd Annual Meeting, to be held October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.
News | ASTRO | October 23, 2020
October 23, 2020 — Be sure to ...